All News Archive — Page 1 of 164

August 26, 2026

Vanderbilt Health mourns passing of global icon Dolly Parton

Legendary songwriter, singer, actress, author and businesswoman, Parton will be remembered for her lasting impact on the lives of millions through her support of everything from pediatric cancer care to infectious disease research at Vanderbilt Health.

(iStock)
August 26, 2026

Duchenne muscular dystrophy patients are focus of GLP-1 therapy for obesity study

The study will begin enrolling eligible patients in September. Thirty participants, ages 12 and older, will be randomized to receive either a placebo or the GLP-1 receptor agonist semaglutide.

Mayur Patel, MD, MPH
August 26, 2026

Mayur Patel receives top honor from Brain Injury Association of America’s Tennessee Chapter

Patel oversees the delivery of trauma, burn, emergency general surgery and critical care, including care for patients sustaining a traumatic brain injury.

(iStock)
August 26, 2026

Vanderbilt Health receives $3.4 million grant to advance breast cancer imaging

MR cytometry is a magnetic resonance imaging technology pioneered by Vanderbilt Health investigators that provides information about tumor microstructure which cannot be obtained from conventional MRI.

Mónica Santisteban, PhD
August 21, 2026

Vanderbilt Health’s Mónica Santisteban to be honored by the American Heart Association

The recognition honors her research that has helped define how high blood pressure can contribute to cognitive impairment and Alzheimer’s disease.

Jordyn Bugarin, 22, was the only patient in the United States enrolled in the OPTIMA clinical trial for fibrodysplasia ossificans progressiva (FOP), a rare genetic condition that causes muscle and connective tissue to turn into bone. (photo by Erin O. Smith)
August 20, 2026

Her muscles are slowly turning to bone. She was the only American in a trial that might stop it.

As part of the clinical trial, Jordyn Bugarin regularly traveled to Vanderbilt Health, navigating a complex study while living with a disease that can flare unpredictably and permanently limit movement. The experimental drug received federal approval on Aug. 19.